Free newsletterPro waitlistHome
Menu
VALREXA PEPTIDE ENCYCLOPEDIA

A biology atlas of the encyclopedia

Open Study Shelf

Explore sourced connections between compounds and body systems, without confusing a place studied with a proven clinical benefit.

Schematic body-system guideA conceptual body outline and numbered regions linked to the text reference below. Positions are approximate, not validated anatomy.1234

1 Brain · 2 Heart · 3 Liver region · 4 Gut region

Conceptual guide only. Not to scale; not all systems are pictured.

Choose a system

Open a system to see what the sources connect to it: production, signaling, handling or experimental research. These are not lists of recommended treatments.

Brain and nervous system

Bremelanotide

The label locates MC4R-expressing neurons in many areas of the central nervous system. It states that the mechanism by which bremelanotide improves HSDD is unknown. Read supporting source ↗

DSIP

A review connects DSIP with sleep regulation, reporting increased slow-wave and delta-wave activity while noting that sleep-inducing findings have been inconsistent. Read supporting source ↗

GHRP-2

The review discusses a hypothalamic pathway in the appetite response associated with growth-hormone secretagogues; it does not establish a specific GHRP-2 brain mechanism. Read supporting source ↗

GHRP-6

The supplied review reports experimental evidence suggesting GHRP-6 may influence sleep architecture, including REM and NREM patterns. Read supporting source ↗

Gonadorelin

The source describes the hypothalamus as the site where endogenous GnRH is synthesized and secreted; this refers to the natural hormone, not manufacture of the synthetic vial product. Read supporting source ↗

Hexarelin

The source connects hexarelin’s growth-hormone-releasing action to the hypothalamic region; it does not establish a broader brain effect here. Read supporting source ↗

Humanin

The review describes humanin as neuroprotective and discusses its reported effects on neuronal cell survival; these findings do not establish clinical benefit. Read supporting source ↗

Kisspeptin-10

The FDA reports that the kisspeptin receptor is enriched in the hypothalamus and describes kisspeptin-expressing hypothalamic neurons projecting to GnRH-expressing neurons. Read supporting source ↗

Metreleptin

The label connects leptin with informing the central nervous system about the body's energy stores; it describes metreleptin as activating the leptin receptor, but does not establish a separate brain-specific clinical effect. Read supporting source ↗

MOTS-c

In mice, regular moderate-intensity running was associated with increased hypothalamic MOTS-c expression; a single exhaustive run was not reported to have that effect. Read supporting source ↗

NAD+

The article reports that a prior study found oral nicotinamide riboside supplementation augmented NAD levels in the brains of people with Parkinson’s disease; this is a report about a related precursor, not direct NAD+ administration. Read supporting source ↗

Oxytocin

Hypothalamic neurons produce oxytocin, and oxytocin neurons also project within the brain; the review connects central signaling with cognition and behavior. Read supporting source ↗

PACAP-38

The review connects PACAP signaling in the hypothalamus and limbic brain regions with CRH-related stress responses, learning, memory, and fear processing; it does not establish a clinical benefit. Read supporting source ↗

Selank

In a rat experiment, Selank administration was connected with changes in the messenger RNA levels of genes involved in neurotransmission in frontal-cortex tissue. Read supporting source ↗

Semax

In a rat focal-ischemia experiment, Semax treatment was associated with changes in gene expression in the ischemic brain cortex. Read supporting source ↗

Setmelanotide

The label connects brain MC4 receptors with regulation of hunger, satiety, and energy expenditure; it describes setmelanotide as an agonist at this receptor. Read supporting source ↗

SHLP2

In mouse experiments, SHLP2 administered outside the brain was detected in cerebrospinal fluid and activated hypothalamic regions, including the arcuate nucleus and dorsomedial hypothalamus. The study links arcuate POMC-neuron activity to SHLP2’s effects on food intake and thermogenesis in mice. Read supporting source ↗

Tirzepatide

The review describes appetite and food-intake effects as likely involving brain regions that regulate feeding, drawing on preclinical studies, human imaging studies, and receptor-expression evidence. Read supporting source ↗

Pituitary

CJC-1295

The FDA discusses the anterior pituitary in relation to a possible mechanism for reduced secretagogue activity of CJC-1295 DAC in rats; this is not evidence of an established mechanism for every CJC-1295 form. Read supporting source ↗

Degarelix

Degarelix binds reversibly to pituitary GnRH receptors; the label connects this binding with reduced gonadotropin and testosterone release. Read supporting source ↗

Ganirelix

The label connects ganirelix action at pituitary gonadotrophs with suppression of pituitary luteinizing hormone and follicle-stimulating hormone secretion. Read supporting source ↗

GHRP-6

The supplied review reports that GHRP-6 stimulates pulsatile growth hormone secretion in controlled human studies; it does not establish a therapeutic benefit from that response. Read supporting source ↗

Goserelin

The source connects goserelin to desensitization of pituitary GnRH receptors and reduced secretion of luteinizing hormone and follicle-stimulating hormone. Read supporting source ↗

Histrelin

The label connects continuous histrelin exposure with reduced responsiveness of pituitary gonadotropes and lower luteinizing hormone and follicle-stimulating hormone levels. Read supporting source ↗

Ipamorelin

FDA says ipamorelin stimulates growth hormone release from the pituitary and identifies pituitary somatotrophs among the sites of ghrelin-receptor activation. Read supporting source ↗

Nafarelin

The label connects nafarelin to pituitary release of LH and FSH, and says repeated dosing abolishes its initial stimulatory effect on the pituitary. Read supporting source ↗

Pasireotide

The label connects pasireotide activation of somatostatin receptors on corticotroph tumor cells with inhibition of ACTH secretion and reduced cortisol secretion. Read supporting source ↗

Thymosin alpha-1

A review connects thymosin alpha-1 with secretion of several pituitary hormones and with suppression of some hypothalamic hormone production; this is a reported neuroendocrine association, not a demonstrated clinical effect. Read supporting source ↗

Pancreas

Dulaglutide

The label connects GLP-1 receptor activation in pancreatic beta cells with increased cyclic AMP and glucose-dependent insulin release; it also reports reduced glucagon secretion. Read supporting source ↗

Eloralintide

The article describes naturally occurring amylin as being co-secreted with insulin by pancreatic beta cells. This is background physiology of native amylin, not evidence that eloralintide is produced by the pancreas. Read supporting source ↗

Exenatide

The label connects exenatide with glucose-dependent insulin secretion from pancreatic beta cells and moderation of glucagon secretion in people with type 2 diabetes. Read supporting source ↗

Insulin aspart

The reference distinguishes the pancreas as the source of naturally produced endogenous insulin; it does not say that injected insulin aspart is produced by the pancreas. Read supporting source ↗

Insulin lispro

The source distinguishes lispro from native human insulin, which it says is normally secreted by the pancreas. It does not say that the pancreas produces administered insulin lispro. Read supporting source ↗

Pasireotide

A review connects stimulation of pancreatic SSTR-5, particularly in islet beta cells, with suppressed insulin secretion relative to glucagon secretion. Read supporting source ↗

Liver

BPC-157

The FDA evaluation reports liver-associated safety signals in animal repeat-dose studies; this does not establish a liver effect in humans. Read supporting source ↗

Enfuvirtide

In vitro studies using human hepatocytes characterized hydrolysis of enfuvirtide to metabolite M3; the source does not establish the liver's contribution to its overall clearance in humans. Read supporting source ↗

Hexarelin

In the reported mouse experiment, hexarelin treatment reduced liver triglycerides; this is an animal finding, not evidence of a human treatment effect. Read supporting source ↗

Histrelin

Human liver cells were used in an in-vitro metabolism study that identified a histrelin metabolite; this is a laboratory finding, not evidence of a measured whole-body liver clearance pathway. Read supporting source ↗

KPV

In a high-fat-diet mouse model, the study reports that oral KPV alleviated an increase in liver mass; this is an animal-model finding. Read supporting source ↗

Metreleptin

The CADTH review describes reduced liver volume during metreleptin treatment in the studied lipodystrophy cohorts; it does not establish metreleptin as a treatment for liver disease. Read supporting source ↗

Palifermin

The label reports the KGF receptor on epithelial cells in the liver; this is a reported receptor location, not evidence of a therapeutic effect in the liver. Read supporting source ↗

SHLP2

In high-fat-diet-fed male mice, SHLP2 administration was associated with reduced liver fat accumulation and lower expression of lipogenic genes. This is an animal-study finding, not evidence of a liver benefit in people. Read supporting source ↗

Tesamorelin

The label identifies hepatocytes as cells on which growth hormone acts and the liver as one source of IGF-1 involved in some growth-hormone effects. This describes the growth-hormone pathway, not a direct tesamorelin action on liver cells. Read supporting source ↗

Gut

BPC-157

In rodent studies, BPC-157-related substances were reported to prevent colonic fistulas and gastric lesions; the FDA evaluation says human evidence for treating ulcerative colitis is insufficient. Read supporting source ↗

Epitalon

In rats, the review reports that Epitalon partly or fully reversed pinealectomy-associated changes in measured gastric endocrine-cell counts, depending on the treatment duration described in the review. Read supporting source ↗

Glucagon

The product label describes glucagon as relaxing smooth muscle in the stomach, small intestine, and colon; this is a pharmacologic effect, not a claim about a gut source of mature glucagon. Read supporting source ↗

Icatibant

The label includes abdominal pain in the symptom score used to assess acute hereditary-angioedema attacks; this describes a trial assessment, not a general claim about gut physiology. Read supporting source ↗

Linaclotide

Linaclotide acts locally at the intestinal epithelial surface; the described GC-C signaling increases intestinal fluid secretion and accelerates transit. Read supporting source ↗

Palifermin

The label reports the KGF receptor on epithelial cells in the stomach and intestine; this establishes reported receptor presence, not a demonstrated clinical benefit in those organs. Read supporting source ↗

Retatrutide

A human phase 1b substudy found that retatrutide delayed emptying of a liquid meal, measured using acetaminophen absorption; the effect was largest after the first dose and diminished with continued treatment. Read supporting source ↗

Secretin

The source connects secretin with bicarbonate release from duodenal Brunner glands, buffering acidic chyme and reducing acid secretion by parietal cells. Read supporting source ↗

Telavancin

The product information warns that antibacterial treatment can be associated with colitis, including illness linked to Clostridium difficile; this is a treatment-related risk, not a claimed therapeutic role in the gut. Read supporting source ↗

Kidneys

ARA-290 / Cibinetide

In the small diabetic macular edema trial, urinary albumin-to-creatinine ratio was assessed as an indicator of kidney injury; all four participants with abnormal baseline results had improved indices at week 12. This is an observation in a small uncontrolled trial, not established kidney benefit. Read supporting source ↗

Carfilzomib

The prescribing information reports acute renal failure in patients receiving Kyprolis and describes renal insufficiency, including renal failure, among reported events. Read supporting source ↗

Dalbavancin

The label reports urinary excretion of unchanged dalbavancin and a urinary metabolite; it also describes reduced clearance in people with impaired renal function. Read supporting source ↗

Telavancin

The kidneys are the major route of telavancin elimination; the product information also identifies renal injury and renal-function monitoring as relevant to treatment. Read supporting source ↗

Teriparatide

Teriparatide has the same stated calcium- and phosphate-homeostasis actions as endogenous parathyroid hormone; the source connects those actions to kidney function, including tubular calcium reabsorption and phosphate handling. Read supporting source ↗

Heart and blood

Abaloparatide

In a study of healthy subjects, the label reports an increase in heart rate after abaloparatide; it reports no clinically meaningful effect on corrected QT intervals or cardiac electrophysiology. Read supporting source ↗

Aprotinin

The label connects aprotinin use during cardiopulmonary bypass surgery with reduced bleeding and reduced need for allogeneic blood transfusions. Read supporting source ↗

Bivalirudin

The label connects bivalirudin to blood coagulation: it inhibits thrombin, a protein involved in forming and stabilizing thrombi, and has anticoagulant effects. Read supporting source ↗

Bremelanotide

The label reports transient increases in blood pressure and decreases in heart rate after bremelanotide administration; these are reported physiological effects, not evidence of cardiovascular benefit. Read supporting source ↗

Carfilzomib

The prescribing information reports cardiac failure and arrhythmias in clinical studies and warns of cardiac toxicities; it does not establish that every reported event was caused by carfilzomib. Read supporting source ↗

CJC-1295

Studies of CJC-1295 DAC of unspecified form in healthy adults reported systemic vasodilatory reactions, transient hypotension, and increased heart rate. Read supporting source ↗

Daptomycin

The product label connects daptomycin to treatment of Staphylococcus aureus bloodstream infections in adults, including right-sided infective endocarditis. Read supporting source ↗

Desmopressin

The review connects desmopressin to endothelial release of von Willebrand factor and factor VIII, which it describes as supporting platelet adhesion and haemostasis. Read supporting source ↗

Ecallantide

The label places plasma kallikrein in the kallikrein-kinin system and describes its conversion of high-molecular-weight kininogen to bradykinin, which it identifies as a vasodilator. This describes the pathway connection, not a proven clinical benefit to the cardiovascular system. Read supporting source ↗

Icatibant

In a bradykinin-challenge study in healthy subjects, intravenous icatibant inhibited the development of bradykinin-induced hypotension, vasodilation, and reflex tachycardia; the label says the clinical significance of these findings is unknown. Read supporting source ↗

Insulin degludec

The source describes circulating serum albumin binding degludec and carrying it through the bloodstream; reversible binding is said to buffer its diffusion into peripheral tissues. Read supporting source ↗

Oritavancin

The label reports that oritavancin is bound to human plasma proteins and is distributed into tissues; this is pharmacokinetic information, not a claimed benefit to the blood system. Read supporting source ↗

PACAP-38

A human observational study found higher plasma PACAP-38 levels in people with cluster headache than in headache-free controls. This is an observed association, not evidence that PACAP-38 causes the condition. Read supporting source ↗

Selank

A human study measured enkephalin activity in blood serum during Selank treatment and reported a treatment-associated change in a serum enkephalin parameter. Read supporting source ↗

Semax

In the same model, Semax treatment was associated with altered expression of genes related to vascular-system processes; this is a gene-expression finding, not evidence of a clinical vascular benefit. Read supporting source ↗

Teduglutide

The label reports fluid overload and congestive heart failure in clinical studies and describes these observations as related to enhanced fluid absorption associated with GATTEX. Read supporting source ↗

Terlipressin

In patients with hepatorenal syndrome type 1, the label reports increases in blood pressure and a decrease in heart rate after terlipressin administration. Read supporting source ↗

Bone

Histrelin

In the pediatric central precocious puberty studies, bone-age advancement was among the assessments used to evaluate disease stabilization during treatment. Read supporting source ↗

Nafarelin

The label connects the treatment-associated low-estrogen state to loss of bone mineral and reports measured decreases in bone mass during treatment. Read supporting source ↗

SHLP2

In a laboratory model using mouse pre-osteoblastic cells exposed to oxidative stress, SHLP2 treatment was associated with improved cell viability and osteogenic measures. The source calls for further work, including in vivo studies, to test relevance to bone conditions. Read supporting source ↗

Skin

BPC-157

Preclinical studies summarized in a review connect BPC-157 with wound-healing outcomes in animal models; this is not evidence of established benefit in people. Read supporting source ↗

Daptomycin

The product label connects daptomycin to treatment of complicated skin and skin-structure infections caused by specified susceptible Gram-positive bacteria. Read supporting source ↗

Icatibant

The label describes skin swelling and skin pain as components of a symptom score used to assess acute hereditary-angioedema attacks in a clinical trial. Read supporting source ↗

Oritavancin

The label connects oritavancin treatment to acute bacterial skin and skin-structure infections in adults caused by susceptible listed Gram-positive microorganisms. Read supporting source ↗

Palifermin

The label reports the KGF receptor on epithelial cells in the skin, including hair follicles and sebaceous glands; it does not establish a clinical benefit there. Read supporting source ↗

Immune system

Aprotinin

The FDA label connects aprotinin’s inhibition of mediators such as kallikrein and plasmin with attenuation of inflammatory responses, and reports effects on pro-inflammatory cytokine release and granulocyte adhesive glycoproteins. Read supporting source ↗

ARA-290 / Cibinetide

The article connects innate repair receptor signaling with an anti-inflammatory and reparative response, particularly in macrophage and microglial populations. This is background mechanistic context, not proof of clinical benefit from cibinetide. Read supporting source ↗

CJC-1295

The FDA notes that antibody formation was not fully assessed and raises a concern that antibodies to CJC-1295-related substances could cross-react with endogenous GHRH; it does not establish that this occurred. Read supporting source ↗

Ecallantide

The label connects C1-esterase inhibitor with regulation of complement and the intrinsic coagulation pathway, and describes the kallikrein-kinin cascade as involved in inflammatory pathways. It does not establish a general immune-system benefit from ecallantide. Read supporting source ↗

Enfuvirtide

The label connects enfuvirtide use with CD4-cell counts and describes its intended action as blocking HIV-1 entry into CD4+ cells; it does not establish a general immune benefit. Read supporting source ↗

Epitalon

In a mouse-cell experiment, Epitalon was reported to raise IL-2 messenger RNA in splenocytes at the measured early time point; this is a laboratory finding, not evidence of a human immune effect. Read supporting source ↗

KPV

In immortalized human bronchial epithelial cells, KPV was associated with suppression of inflammatory signaling and chemokine secretion; these are laboratory findings, not evidence of benefit in people with lung disease. Read supporting source ↗

PACAP-38

The migraine article describes PACAP-38 as capable of degranulating meningeal mast cells, which release mediators that may affect meningeal nociceptors. The article presents this as one possible mechanism, not a settled explanation. Read supporting source ↗

Polymyxin B

A review describes binding to lipid A as neutralizing lipopolysaccharide, but says the proposed prevention of septic shock is not clearly understood. Read supporting source ↗

Selank

The article describes Selank as having immunomodulatory activity, but the supplied article does not report an immune-system experiment establishing that activity. Read supporting source ↗

Semax

In that rat ischemia model, Semax altered expression of immune-related genes, including genes associated with chemokines and immunoglobulins. Read supporting source ↗

Cellular processes

AOD-9604

In obese mice, treatment was associated with increased beta-3 adrenergic receptor RNA expression, a receptor the study describes as a major lipolytic receptor in fat cells. The study concluded that the lipolytic actions were not mediated directly through that receptor. Read supporting source ↗

ARA-290 / Cibinetide

The article describes endothelial cells and neurons as cell types involved in the tissue-protective effects associated with innate repair receptor signaling; it does not establish these effects as clinical outcomes of cibinetide in the reported trial. Read supporting source ↗

Carfilzomib

The FDA review describes antiproliferative and proapoptotic activity in tumor cells in vitro; this is a laboratory finding, not evidence of clinical benefit in every tumor type. Read supporting source ↗

CBL-514

The article connects CBL-514 with adipocyte apoptosis in nonclinical studies; it identifies this as a reported activity, not an established molecular target. Read supporting source ↗

CT20p

In the reported cell experiments, nanoparticle-delivered CT20p interacted with intracellular CCT in breast cancer cells; treatment was associated with cytoskeletal disruption, reduced migration, detachment, and cell death. These are experimental findings, not evidence of a clinical effect in people. Read supporting source ↗

Daptomycin

Daptomycin acts on susceptible bacterial membranes; the source describes membrane depolarization and downstream inhibition of bacterial DNA, RNA, and protein synthesis. Read supporting source ↗

Ecallantide

At the molecular level, the label says ecallantide binds plasma kallikrein and inhibits its activity; it does not specify a cellular location for this target. Read supporting source ↗

Eptifibatide

At the cellular level, the label identifies the platelet glycoprotein IIb/IIIa receptor as the binding site and states that eptifibatide inhibits platelet aggregation. Read supporting source ↗

KPV

In human bronchial epithelial cell experiments, KPV was associated with reduced nuclear entry of the NF-κB p65 subunit and interference with its interaction with importin-α3. Read supporting source ↗

Linaclotide

The label connects GC-C activation in intestinal epithelial cells to increased intracellular and extracellular cGMP; it does not describe a body-wide cellular effect. Read supporting source ↗

MOTS-c

In cells exposed to metabolic stress, MOTS-c can move into the nucleus and is linked to regulation of stress-adaptation gene expression. Read supporting source ↗

NAD+

NAD is connected to cellular energy metabolism through oxidation-reduction reactions, including glycolysis, fatty-acid oxidation, the Krebs cycle, and oxidative phosphorylation. Read supporting source ↗

Nesiritide

The label connects nesiritide's receptor binding on vascular smooth muscle and endothelial cells with increased intracellular cyclic GMP and smooth-muscle relaxation. Read supporting source ↗

Romidepsin

In laboratory experiments, romidepsin was associated with acetylated-histone accumulation, cell-cycle arrest, and apoptosis in some cancer cell lines; this is not a claim of established benefit in people. Read supporting source ↗

TB-500

TB-500 and its metabolites were assessed in fibroblast cytotoxicity and wound-healing experiments in vitro; the source does not establish an organ-level effect. Read supporting source ↗

Teduglutide

The identified receptor is reported in intestinal subpopulations of enteroendocrine cells, subepithelial myofibroblasts, and enteric neurons in the submucosal and myenteric plexuses. Read supporting source ↗

Telavancin

Telavancin binds bacterial cell-wall precursors and bacterial membranes; the supplied description connects these actions to inhibition of cell-wall construction and membrane disruption. Read supporting source ↗

Educational reference, not medical advice. A biological connection is not proof of clinical benefit. Editorial additions dated November 11, 2026; this is not an independent expert-review date.